NCT03911817View on ClinicalTrials.gov

Impact of Midodrine Administration on the Clinical Outcome of Septic Shock Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 15, 2017

Primary Completion Date

June 30, 2019

Study Completion Date

July 30, 2019

Conditions
Septic Shock
Interventions
DRUG

Midodrine

The oral vasoactive drug (Midodrine) at a dose of 10-20 mg every 8 hours will be used in one arm .After the blood pressure goal is met for more than 24 hours without IV vasopressor ,midodrine will be discontinued prior to discharge

Trial Locations (1)

Unknown

Critical Care Medicine Department - Cairo University Hospitals, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT03911817 - Impact of Midodrine Administration on the Clinical Outcome of Septic Shock Patients | Biotech Hunter | Biotech Hunter